A phase II single-blind, randomized, placebo-controlled trial to study the efficacy and safety of Study Drug administered as adjunctive treatment to patients with acquired thrombotic thrombocytopenic purpura.
The Challenges of Patient Recruitment in Oncology Trials - Part 1
As the oncology environment continues to grow towards more targeted therapies, it is imperative that patient recruitment strategies focus on how to…
The Challenges of Patient Recruitment in Oncology Trials - Part 3
A Phase I through Phase III oncology trial costs approximately $56.3 million and lasts for eight years. In 2012, it was reported that a typical…
Our in-house oncology and hematology experts make the complex, simple. Our